| Generic name | Nivolumab |
| Pronunciation | nye vol' ue mab |
| Brand name(s), other common name(s) | Opdivo® |
| Drug type | Monoclonal antibody |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Nivolumab is FDA approved for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after
- Autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin
- Three or more lines of systemic therapy that includes autologous HSCT
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Side effects needing medical attention
Fatigue, upper respiratory tract infection, fever, diarrhea, and cough.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.